Ashish Saxena

4.0k total citations · 2 hit papers
89 papers, 2.6k citations indexed

About

Ashish Saxena is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Ashish Saxena has authored 89 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 21 papers in Molecular Biology. Recurrent topics in Ashish Saxena's work include Lung Cancer Treatments and Mutations (13 papers), Helicobacter pylori-related gastroenterology studies (13 papers) and Aldose Reductase and Taurine (12 papers). Ashish Saxena is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Helicobacter pylori-related gastroenterology studies (13 papers) and Aldose Reductase and Taurine (12 papers). Ashish Saxena collaborates with scholars based in United States, India and Sweden. Ashish Saxena's co-authors include Jeffrey L. Port, Nasser K. Altorki, Brendon M. Stiles, Timothy E. McGraw, Vivek Mittal, Geoffrey J. Markowitz, Dingcheng Gao, Kota V. Ramana, Satish K. Srivastava and Ravinder Tammali and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ashish Saxena

82 papers receiving 2.6k citations

Hit Papers

The lung microenvironment: an important regulator of tumo... 2018 2026 2020 2023 2018 2021 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The lung microenvironment: an important regulator of tumour growth and metastasis
    2018 795 citations Nasser K. Altorki, Jeffrey L. Port et al. profile →
  2. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial
    2021 210 citations Nasser K. Altorki, Timothy E. McGraw et al. profile →

Peers

Ashish Saxena
Jinglin Xia China
Venkateshwar G. Keshamouni United States
Si Sun China
Kouji Izumi Japan
Mansoor M. Ahmed United States
Kwangmo Yang South Korea
Satoshi Kobayashi Japan
Marco A. De Velasco Japan
Saverio Candido Italy
Dan Su China
Jinglin Xia China
Ashish Saxena
Citations per year, relative to Ashish Saxena Ashish Saxena (= 1×) peers Jinglin Xia

Countries citing papers authored by Ashish Saxena

Since Specialization
Citations

This map shows the geographic impact of Ashish Saxena's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ashish Saxena with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ashish Saxena more than expected).

Fields of papers citing papers by Ashish Saxena

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ashish Saxena. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ashish Saxena. The network helps show where Ashish Saxena may publish in the future.

Co-authorship network of co-authors of Ashish Saxena

This figure shows the co-authorship network connecting the top 25 collaborators of Ashish Saxena. A scholar is included among the top collaborators of Ashish Saxena based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ashish Saxena. Ashish Saxena is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jannat‐Khah, Deanna, Fenglong Xie, Ashish Saxena, Jeffrey R. Curtis, & Anne R. Bass. (2025). Survival in Immune Checkpoint Inhibitor–Treated Patients With Rheumatoid Arthritis and Non–Small Cell Lung Cancer: An Observational Cohort Study. Arthritis Care & Research. 77(10). 1214–1221.
2.
Jannat‐Khah, Deanna, Jeffrey R. Curtis, Fenglong Xie, Ashish Saxena, & Anne R. Bass. (2025). Are Glucocorticoids Associated With Worse Survival Among Patients With Rheumatoid Arthritis and Lung Cancer Treated With Immune Checkpoint Inhibitors?. Arthritis & Rheumatology.
3.
Derry, Heather M., Holly G. Prigerson, Jessica Hahne, et al.. (2025). “You Always Worry”: Scan-Related Anxiety Among Patients With Metastatic Lung Cancer. Journal of the American College of Radiology. 22(12). 1572–1577.
4.
Saxena, Ashish, et al.. (2023). Advancements in small cell lung cancer. Seminars in Cancer Biology. 93. 123–128. 33 indexed citations
5.
Navi, Babak B., Cenai Zhang, Carla Sherman, et al.. (2022). Ischemic stroke with cancer: Hematologic and embolic biomarkers and clinical outcomes. Journal of Thrombosis and Haemostasis. 20(9). 2046–2057. 22 indexed citations
6.
Saxena, Ashish, et al.. (2022). Automated Retinal Vascular Topological Information Extraction From OCTA. 2022 44th Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC). 2022. 1839–1842. 1 indexed citations
7.
Daly, Megan E., Nofisat Ismaila, Roy H. Decker, et al.. (2021). Radiation Therapy for Small-Cell Lung Cancer: ASCO Guideline Endorsement of an ASTRO Guideline. Journal of Clinical Oncology. 39(8). 931–939. 40 indexed citations
8.
Saxena, Ashish, Matthew S. Walters, Jae-Hung Shieh, et al.. (2021). Extracellular vesicles from human airway basal cells respond to cigarette smoke extract and affect vascular endothelial cells. Scientific Reports. 11(1). 6104–6104. 15 indexed citations
9.
Saxena, Ashish, Jeffrey L. Port, Benjamin E. Lee, et al.. (2021). Lung Cancer Stage Shift as a Result of COVID-19 Lockdowns in New York City, a Brief Report. Clinical Lung Cancer. 23(3). e238–e242. 16 indexed citations
10.
Epstein, Andrew S., Valerie F. Reyna, Ashish Saxena, et al.. (2020). Development of the Oncolo-GIST (“Giving Information Strategically & Transparently”) Intervention Manual for Oncologist Skills Training in Advanced Cancer Prognostic Information Communication. Journal of Pain and Symptom Management. 62(1). 10–19.e4. 11 indexed citations
11.
Altorki, Nasser K., Alain Borczuk, Ashish Saxena, et al.. (2019). P2.04-92 Neoadjuvant Durvalumab With or Without Sub-Ablative Stereotactic Radiotherapy (SBRT) in Patients with Resectable NSCLC (NCT02904954). Journal of Thoracic Oncology. 14(10). S746–S746. 14 indexed citations
12.
Linehan, W. Marston, Viola W. Zhu, Adam J. Schoenfeld, et al.. (2018). Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. Journal of Thoracic Oncology. 13(10). 1530–1538. 54 indexed citations
13.
Sonowal, Himangshu, Pabitra Bikash Pal, Kirtikar Shukla, et al.. (2018). Aldose reductase inhibitor, fidarestat prevents doxorubicin-induced endothelial cell death and dysfunction. Biochemical Pharmacology. 150. 181–190. 29 indexed citations
14.
Shukla, Kirtikar, Himangshu Sonowal, Ashish Saxena, & Kota V. Ramana. (2018). Didymin prevents hyperglycemia-induced human umbilical endothelial cells dysfunction and death. Biochemical Pharmacology. 152. 1–10. 32 indexed citations
15.
16.
Saxena, Ashish, et al.. (2015). Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer: What Is Old Is New Again. The Oncologist. 20(8). 934–945. 31 indexed citations
17.
Saxena, Ashish, et al.. (2014). QUANTIFICATION OF URAPIDIL IN HUMAN PLASMA USING ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY–ELECTROSPRAY IONIZATION MASS SPECTROMETRY (UPLC–MS/MS) FOR PHARMACOKINETIC STUDY IN HEALTHY INDIAN VOLUNTEERS. International Journal of Pharmacy and Pharmaceutical Sciences. 6(10). 565–570. 1 indexed citations
18.
19.
Saxena, Ashish, Mohammad Shoeb, Kota V. Ramana, & Satish K. Srivastava. (2013). Aldose reductase inhibition suppresses colon cancer cell viability by modulating microRNA-21 mediated programmed cell death 4 (PDCD4) expression. European Journal of Cancer. 49(15). 3311–3319. 36 indexed citations
20.
Tammali, Ravinder, Aramati B. M. Reddy, Ashish Saxena, et al.. (2011). Inhibition of aldose reductase prevents colon cancer metastasis. Carcinogenesis. 32(8). 1259–1267. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jinglin Xia Breakdown of academic impact, for papers by Venkateshwar G. Keshamouni Breakdown of academic impact, for papers by Si Sun Breakdown of academic impact, for papers by Kouji Izumi Breakdown of academic impact, for papers by Mansoor M. Ahmed Breakdown of academic impact, for papers by Kwangmo Yang Breakdown of academic impact, for papers by Satoshi Kobayashi Breakdown of academic impact, for papers by Marco A. De Velasco Breakdown of academic impact, for papers by Saverio Candido Breakdown of academic impact, for papers by Dan Su
Rankless by CCL
2026